Nitin Jain, MD, and Richard R. Furman, MD, review the role of BTK inhibitors and emerging therapies on the horizon for the management of CLL.
EP. 1: BTK Inhibitors in the Management of CLL
Nitin Jain, MD, and Richard R. Furman, MD, review available treatment options for the treatment of CLL and discuss the safety and tolerability of these therapies.
EP. 2: ELEVATE-RR and ALPINE Trials in Relapsed CLL
Richard R. Furman, MD, leads the discussion on clinical implications from head-to-head trials of BTK inhibitors in the relapsed setting for patients with CLL.
EP. 3: Role of Fixed-Dose Regimens in CLL
Nitin Jain, MD, leads the discussion on the use of fixed-dose regimens for the treatment of CLL as seen in the phase 2 CAPTIVATE and phase 3 GLOW trials.
EP. 4: Resistance Mechanisms to BTKi in CLL
Richard R. Furman, MD, reviews resistance mechanisms to BTK inhibitors and how they affect treatment selection for patients with CLL.
EP. 5: Using Noncovalent BTK Inhibitors for the Management of CLL
Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.
EP. 6: Choosing the Appropriate Treatment Strategy in CLL
Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.
EP. 7: Novel Treatments for the Management of CLL
Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.
EP. 8: Q&A: Modifying and Switching Therapies in CLL
Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.
EP. 9: Q&A: Early Treatment of CLL
Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.
Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist
Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer
Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC